Guide

Microdose Tirzepatide: Evidence, Cost and Limitations

What you are actually buying

A microdose programme prescribes well below the doses used in the pivotal trials. Typical programmes deliver around 1 mg a week. SURMOUNT-1 used 5, 10 and 15 mg, and reported mean reductions of roughly 15.0%, 19.5% and 20.9% respectively over 72 weeks against 3.1% with placebo.

The dose-response relationship is the whole story. If effect rises from 5 to 15 mg, a dose below 5 mg cannot be assumed to match any of those figures. No trial has published what 1 mg does.

The regulatory mechanics, stated plainly

Compounding a copy of an available approved product is generally not permitted. Compounding something a prescriber documents as clinically different for an individual patient is. "Personalised dosing" is the mechanism by which that documentation happens, which is why the microdose category expanded when the shortage listings ended rather than when new evidence appeared.

That is not an accusation of bad faith. It is the regulatory context, and it explains the timing better than a clinical rationale does.

The pricing

NexLife (opens nexlife.us in a new tab) at $147 on a twelve-month plan and $189 month-to-month, verified. Enhance.MD at $169 for a stated 1 mg weekly programme including lab testing, delivered twelve-weekly. Shed at $199 with a two-month minimum. bmiMD at $349, which is above most competitors' standard injectable pricing.

For context, the cheapest FDA-approved GLP-1 is $149 a month — orforglipron or oral Wegovy tablets at starting doses. Two microdose programmes cost more than an approved product with published trial data.

Where a lower dose is legitimate

Prescribers reduce doses for real clinical reasons: side-effect burden, comorbidities, patient preference, or maintenance after a period at full dose. A clinician choosing a lower dose for a specific patient is practising medicine, and a patient who cannot tolerate 10 mg is better served at 5 than at nothing.

That differs from a programme built around a low dose as its commercial entry tier and marketed beside figures collected at ten to fifteen times the dose.

Four questions before enrolling

1. What weekly dose does this deliver, in milligrams?
2. What evidence exists for that dose specifically?
3. Is the plan to escalate, and does the price change if I do?
4. If this is maintenance dosing, what was I meant to have done first?

Questions readers actually ask

Capture standing: 35 of 86 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.